ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 97 filers reported holding ALX ONCOLOGY HLDGS INC in Q1 2022. The put-call ratio across all filers is 0.84 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $201,360 | -36.1% | 41,950 | 0.0% | 0.16% | -18.9% |
| Q2 2023 | $315,045 | +66.2% | 41,950 | 0.0% | 0.20% | +55.8% |
| Q1 2023 | $189,614 | -59.9% | 41,950 | 0.0% | 0.13% | -60.4% |
| Q4 2022 | $472,777 | +17.9% | 41,950 | 0.0% | 0.33% | +27.3% |
| Q3 2022 | $401,000 | +18.3% | 41,950 | 0.0% | 0.26% | +9.9% |
| Q2 2022 | $339,000 | -52.2% | 41,950 | 0.0% | 0.23% | -30.7% |
| Q1 2022 | $709,000 | -21.4% | 41,950 | 0.0% | 0.34% | +25.8% |
| Q4 2021 | $902,000 | -70.9% | 41,950 | 0.0% | 0.27% | -73.1% |
| Q3 2021 | $3,098,000 | +62.1% | 41,950 | +20.0% | 0.99% | +67.0% |
| Q2 2021 | $1,911,000 | – | 34,950 | – | 0.59% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |